0001305773-21-000142.txt : 20211223 0001305773-21-000142.hdr.sgml : 20211223 20211223083253 ACCESSION NUMBER: 0001305773-21-000142 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211223 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211223 DATE AS OF CHANGE: 20211223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Conformis Inc CENTRAL INDEX KEY: 0001305773 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37474 FILM NUMBER: 211514915 BUSINESS ADDRESS: STREET 1: 600 TECHNOLOGY DRIVE CITY: BILLERICA STATE: MA ZIP: 01821 BUSINESS PHONE: (781) 345-9001 MAIL ADDRESS: STREET 1: 600 TECHNOLOGY DRIVE CITY: BILLERICA STATE: MA ZIP: 01821 FORMER COMPANY: FORMER CONFORMED NAME: ConforMIS Inc DATE OF NAME CHANGE: 20041013 8-K 1 cfms-20211223.htm 8-K cfms-20211223
0001305773FALSE00013057732021-12-232021-12-23



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 23, 2021
Conformis, Inc.
(Exact Name of Company as Specified in Charter)
 
Delaware001-3747456-2463152
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

600 Technology Park Drive
Billerica, MA 01821
(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code: (781) 345-9001

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.00001 par value per shareCFMSThe Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 17, 2021, Brent Alldredge, Chief Legal Officer and Corporate Secretary of Conformis, Inc. (the “Company”), notified the Company that he is resigning from his position, effective January 16, 2022. As part of his transition, on December 22, 2021, the Company entered into a consulting agreement (the “Consulting Agreement”) with Mr. Alldredge, effective as of December 17, 2021, pursuant to which Mr. Alldredge will provide consulting, transition and similar services to the Company following his departure until February 25, 2022, unless earlier terminated or extended by the parties. In exchange for Mr. Alldredge’s services, the Company will pay Mr. Alldredge $500 per hour, up to a maximum of $5,000 per week, unless an increase is approved by the Company’s Chief Executive Officer. Upon the expiration or termination of the Consulting Agreement, the Company will pay Mr. Alldredge an additional $10,000, subject to execution of a certificate by Mr. Alldredge which provides for, among other things, return of Company property and continuing confidentiality obligations.

The foregoing summary of the Consulting Agreement is subject to, and qualified in its entirety by, the full text of such agreement, which is filed as Exhibit 10.1 hereto.

Item 7.01.
Regulation FD Disclosure.
On December 23, 2021, the Company issued a press release announcing Mr. Alldredge’s departure. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

The information contained in this Item 7.01, including the press release attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CONFORMIS, INC.
Date: December 23, 2021
By:
/s/ Robert S. Howe
Robert S. Howe
Chief Financial Officer


EX-10.1 2 ex-101_balldredgeconsultin.htm EX-10.1 Document

Conformis, Inc.
CONSULTING AGREEMENT
THIS CONSULTING AGREEMENT (this “Agreement”), dated December 22, 2021 but effective as of January 17, 2021 (the “Effective Date”), is by and between Conformis, Inc., a Delaware corporation (the “Company”), and J. Brent Alldredge, an individual with an address listed on the signature page hereto (the “Consultant”).
WHEREAS, the Company desires consulting and similar services relating to the Company’s business and products; and
WHEREAS, the Consultant desires to contract with the Company to perform such services.
NOW, THEREFORE, in consideration of the mutual covenants hereinafter recited, the sufficiency of which is hereby acknowledged, the parties agree as follows:
1.Scope of Work. The Consultant will perform the services set forth in Exhibit A attached hereto (the “Services”). Any additions to or modifications of the Services will be set forth in writing and will be signed by both parties in advance of the Consultant performing such additional or modified Services. The performance of Services and the compensation for Services necessary to the completion of such additions or modifications will be governed by this Agreement unless otherwise described in a written agreement of the parties.
2.Term. The Consultant will serve as a consultant to the Company for a period commencing on the Effective Date and concluding when terminated in accordance with Section 9 of this Agreement (the “Term”).
3.Consulting Fees. The Company agrees to pay the Consultant for the Services in accordance with the payment schedule set forth in Exhibit B attached hereto.
4.Documentation of Services and Payments. The Consultant will include with all invoices submitted to the Company an itemization and description of all Services for which the Consultant requests compensation with reasonable specificity to allow the Company to adequately account for such Services. The Company will pay each undisputed invoice submitted hereunder within 30 days of receipt thereof.
5.Noninterference; Noncompetition. Consultant shall abide by Sections 11.2 - 11.5 of the Employee Confidential Information, Inventions and Non-Competition Agreement by and between the Company and the Consultant (the “Non-Compete Agreement”), which was attached as Exhibit A to the Consultant’s July 29, 2019 Employment Agreement (the “Employment Agreement”), which sections are incorporated herein by reference. For clarity, the “Non-competition Period” described in Section 11.2 of the Non-Compete Agreement shall begin running as of the first day following Consultant’s last day of employment with the Company.
6.Confidentiality.
(a)Definition. For purposes of this Agreement, “Confidential Information” means all non-public, confidential or proprietary information disclosed on or after the Effective Date by the Company (including any parent, subsidiary or affiliate of the Company, and any person or entity directly or indirectly controlled by or controlling the Company, or in which any of the aforesaid have at least a 50% interest) or its representatives to the Consultant relating to any of the Company’s or a third party’s technology and/or business including, without limitation, this Agreement, Inventions (as defined below), any other inventions, trade secrets, patents, ideas, licenses, research and development, software, or other intellectual property, manufacturing plans, operations, business plans, finance plans, financial information, marketing plans, customer information, information regarding vendors and suppliers, products, services, strategic partnerships, or other information of Company or a third party known to be confidential or proprietary, and/or other information of Company or a third party that reasonably should be known to be confidential or proprietary. Confidential Information may be in any form, including, without limitation, oral, written, and/or electronic form, and further includes, for example, notes, compilations, reports, databases, summaries and other materials prepared by or for the Consultant that contain, are based on, or derived from, in whole or in part, Confidential Information. Confidential Information does not
Consulting Agreement—Conformis, Inc. / J. Brent Alldredge
January 17, 2022        Page 1


include information that the Consultant can document (a) is (through no improper action or inaction of the Consultant) generally known by the public, (b) is rightfully in the Consultant’s possession or rightfully known by the Consultant prior to receipt by the Company and was not disclosed in violation of any restrictions regarding confidentiality, (c) became available to the Consultant rightfully from a third party, and was not disclosed in violation of restrictions on confidentiality, or (d) was or is developed independently by the Consultant without reference to or use of, in whole or in part, any Confidential Information. For clarity, the Non-Compete Agreement shall apply to Proprietary Information (as defined in the Non-Compete Agreement) received by Consultant prior to the Effective Date and nothing in this Agreement shall modify Consultant’s obligations to the Company under the Non-Compete Agreement. Further, the parties agree that during the term of this Agreement, the Company shall not provide to Consultant, and Consultant shall not accept, any Confidential Information that is not related to patient-specific, patient-matched and/or patient-engineered orthopedic implants and instruments for the knee and hip.
(b)Nondisclosure. The Consultant acknowledges that Confidential Information is of great value to the Company. Accordingly, the Consultant agrees to hold all Confidential Information in confidence and not disclose, use, copy, publish, summarize or, if applicable, remove from the premises of the Company any Confidential Information. Upon the expiration or termination of this Agreement, the Consultant agrees (i) to promptly deliver to the Company all papers, records, data, notes, drawings, files, documents, samples, devices, products, equipment and other materials, including copies and in whatever form, relating to the Company that the Consultant possesses or creates, whether or not confidential or proprietary, (ii) to not disclose, use, copy, publish, summarize or, if applicable, remove from the premises of the Company any Confidential Information, and (iii) to promptly execute and deliver to the Company the “Termination Certificate” attached hereto as Exhibit C.
7.Inventions and Original Works of Authorship.
(a)Definition. For purposes of this Agreement, “Inventions” means any and all ideas and discoveries, including, without limitation, inventions, trade secrets, original works of authorship, findings, reports, disclosures, processes, systems, methods, formulae, procedures, concepts, compositions, techniques, drawings, models, diagrams, flow charts, research, data, devices, machinery, intellectual property, instruments, materials, products, patterns, compilations, programs, techniques, sequences, designs, specifications, documentation, algorithms, software, computer programs, source code, object code and mask works, as well as improvements thereof or know-how related thereto, whether copyrightable or patentable or not, which are made by the Consultant, alone or in combination with others, (i) pursuant to, related to or resulting from the provision of Services or other tasks by the Consultant under this Agreement or any other agreement with the Company, or (ii), during the Term, that involve patient-specific, patient-matched and/or patient-engineered orthopedic implants, instruments and surgical procedures for the knee, hip, shoulder or ankle, or (iii) with the use of or as a result of access to Confidential Information, including, without limitation, any derivative work which constitutes an improvement or modification to any Confidential Information, such as any design, drawing, or product that embodies Confidential Information.
(b)Ownership and Assignment. All Inventions are and shall be the sole and exclusive property of the Company and/or its nominees or assigns. Consultant hereby assigns to the Company any and all right, title and interest Consultant has, may have, or may acquire in all Inventions, and also all intellectual property rights relating thereto. To the extent that ownership of, or any rights to, any such Inventions does not immediately or automatically vest in the Company, the Consultant hereby assigns and agrees to assign to the Company or its designees, without further consideration, the Consultant’s entire right, title, and interest in and to all such existing and future Inventions, including, without limitation, all rights to obtain, register, perfect, litigate, enforce and otherwise exploit inventions, patents, copyrights, trade secrets, and other intellectual property rights and protections with respect thereto (whether or not patent or copyright applications are filed thereon). The Consultant will promptly notify the Company in writing of all Inventions so conceived or made by the Consultant. The Consultant shall have no license to or rights of any kind, including, including any such contractual rights or rights by operation of law, to any Inventions, unless explicitly granted by Company in writing in a separate agreement.
(c)Power of Attorney. During the Term and as necessary thereafter, the Consultant will assist the Company (at the Company’s expense) in performing any and all tasks and other actions reasonably necessary to obtain and enforce patents, copyrights, mask work rights, and other forms of intellectual property protection on Inventions, and to fulfill any and all related duties and obligations required by law. If the Company is unable because of the mental or physical incapacity of the
Consulting Agreement—Conformis, Inc. / J. Brent Alldredge
January 17, 2022        Page 2


Consultant or for any other reason to secure the signature of the Consultant to apply for or to pursue any application for any United States or foreign letters patent or copyright registrations covering Inventions assigned to the Company pursuant to Section 7(b), then the Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Consultant’s agent and attorney in fact, to act for and on the Consultant’s behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon.
(d)Moral Rights. The Consultant also hereby irrevocably transfers and assigns to Company, and agrees to irrevocably transfer and assign to Company, and waives and agrees never to assert, any and all “Moral Rights” (as defined below) that the Consultant may have in or with respect to any Inventions, during and after the Term. “Moral Rights” mean any rights to claim authorship of any Invention, to object to or prevent the modification or destruction of any Invention, to withdraw from circulation or control the publication or distribution of any Invention, and any similar right, existing under judicial or statutory law of any country in the world, or under any treaty, regardless of whether or not such right is called or generally referred to as a “moral right.”
(e)Patent Applications. If the Company files an original United States patent application covering any invention of which the Consultant is a named inventor, the Consultant will receive an inventor’s fee of $100.
(f)Further Assurances. The Consultant will execute such documents as the Company will reasonably require to evidence and confirm the transfer of rights to the Company made under this Agreement.
8.Publishing. As provided in Sections 6 and 7 above, data resulting from the Consultant’s provision of Service pursuant to this Agreement, or the use of or access to Confidential Information, shall be an Invention owned by the Company and subject to confidential treatment. The Consultant shall not directly or indirectly (including, without limitation, by publication) disclose any such data or other Company Inventions or Confidential Information without the prior written consent of the Company. The Company shall have full editorial control with respect to any proposed publication by the Consultant that includes or makes reference to such data or other Company Inventions or Confidential Information (with the prior written consent of the Company), including without the limitation the rights to (a) not publish or make public such data or other Company Inventions or Confidential Information, (b) remove any such data or other Company Inventions or Confidential Information contained therein, and (c) protect its rights to any patentable Inventions set forth therein. As provided in Section 7 above, any such publication shall be an Invention owned by the Company.
9.Termination. This Agreement will automatically terminate as stated in Exhibit A. In the event of any termination of this Agreement, the Company will make payments to the Consultant for all work performed in accordance with the terms and conditions of this Agreement up to the date of termination, and the Consultant will immediately return to the Company, without limitation, all documents, drawings and any other items of whatever nature supplied to the Consultant by the Company or owned by the Company pursuant to this Agreement.
10.Survival. Each and all of the terms, provisions and/or covenants of each of Sections 5 through 22 of this Agreement will, for any and all purposes whatsoever, survive the termination of this Agreement.
11.Independent Contractor/Taxes. Consultant is not an agent or employee of the Company and has no authority to act on behalf of the Company or to otherwise obligate or bind the Company by contract or otherwise. Except as required by a final determination by the Internal Revenue Service or state taxing authority and upon due notice to the other party, the Consultant and the Company agree to treat the Consultant as an independent contractor for tax purposes and to file all tax and information returns and pay all applicable taxes on that basis.
12.Third Party Contracts. The Consultant represents that, other than with Bruker Corporation and/or its affiliates, and except as disclosed in writing to the Company, (a) there are no other contracts to assign Inventions that are now in existence between any other party and the Consultant, and (b) the Consultant has no employments, consultancies or undertakings which would restrict or impair the Consultant’s performance of this Agreement. The Consultant will not improperly use or disclose any proprietary information or trade secrets of any former or current employer or other third party. The Consultant will not bring onto the premises of the Company any unpublished documents or any property
Consulting Agreement—Conformis, Inc. / J. Brent Alldredge
January 17, 2022        Page 3


belonging to any former or current employer or other third party unless consented to in writing by such employer or such other third party. If, in the course of the Consultant’s performance of this Agreement, the Consultant incorporates a prior Consultant-owned invention into a Company product, process or machine, the Company is hereby granted and will have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, use and sell such prior invention.
13.Assignment. The rights and liabilities of the parties hereto will bind and inure to the benefit of their respective successors, assigns, heirs, executors and administrators, as the case may be; provided, however, that as the Company has specifically contracted for the Services to be provided by the Consultant hereunder, the Consultant may not assign or delegate the Consultant’s obligations under this Agreement either in whole or in part without the prior written consent of the Company.
14.Governing Law; Consent to Jurisdiction. This Agreement will be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts, excluding those laws that direct the application of the laws of another jurisdiction. The Consultant hereby submits to the sole jurisdiction and venue of the courts of the Commonwealth of Massachusetts for purposes of any action or proceeding relating to this Agreement.
15.Injunctive Relief. The Consultant acknowledges and agrees that damages will not be an adequate remedy in the event of a breach of any of the Consultant’s obligations under this Agreement. The Consultant therefore agrees that the Company will be entitled (without limitation of any other rights or remedies otherwise available to the Company and without the necessity of posting a bond or other security) to obtain an injunction from any court of competent jurisdiction prohibiting the continuance or recurrence of any breach of this Agreement.
16.Headings. The headings in this Agreement are intended principally for convenience and will not, by themselves, determine the rights and obligations of the parties to this Agreement.
17.Attorneys’ Fees. The prevailing party in any suit brought to enforce its rights under this Agreement will be entitled to reasonable attorneys’ fees and costs.
18.Notices. All notices, requests, demands, and other communications required by, or made in connection with, this Agreement or the transactions contemplated by this Agreement, will be in writing and will be deemed to have been duly given on the date of delivery, if delivered in person or by overnight mail carrier, or three business days after mailing if mailed by certified or registered mail, postage prepaid, return receipt requested, addressed as follows:
If to the Company:        Conformis, Inc.
600 Technology Park Drive
Billerica, MA 01821
Attention: Chief Executive Officer
If to the Consultant:        The email address listed on the signature page hereto.
Such addresses may be changed, from time to time, by means of a notice given in the manner provided in this Section 18.
19.Severability. If any provision of this Agreement is held to be unenforceable for any reason, such provision will be adjusted rather than voided, if possible, in order to achieve the intent of the parties to the maximum extent possible. In any event, all other provisions of this Agreement will be deemed valid and enforceable to the full extent possible.
20.Waiver. The waiver of any term or condition contained in this Agreement by any party to this Agreement will not be construed as a waiver of a subsequent breach or failure of the same term or condition or a waiver of any other term or condition contained in this Agreement.
21.Counterpart and Facsimile Signatures. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Agreement may be executed by facsimile signature (including signatures in Adobe PDF or similar format).
Consulting Agreement—Conformis, Inc. / J. Brent Alldredge
January 17, 2022        Page 4


22.Entire Agreement; Modifications. Except as otherwise provided herein or in the exhibits hereto, this Agreement represents the entire understanding among the parties with respect to the subject matter of this Agreement, and this Agreement supersedes any and all prior and contemporaneous understandings, agreements, plans, and negotiations, whether written or oral, with respect to the subject matter hereof, including, without limitation, any understandings, agreements, or obligations respecting any past or future compensation, bonuses, reimbursements, or other payments to the Consultant from the Company. For clarity, this Agreement does not modify or supersede the Non-Compete Agreement or the Employment Agreement by and between the Consultant and the Company, as amended from time-to-time. All modifications to the Agreement must be in writing and signed by each of the parties hereto.
[Remainder of Page Intentionally Left Blank]

Consulting Agreement—Conformis, Inc. / J. Brent Alldredge
January 17, 2022        Page 5


IN WITNESS WHEREOF, the parties hereto have executed this Consulting Agreement on December 22, 2021 with a deemed Effective Date of January 17, 2022.
Company:                    Conformis, Inc.


By:    /s/ Mark A. Augusti
    Mark A. Augusti
    Chief Executive Officer




Consultant:     /s/ J. Brent Alldredge
    J. Brent Alldredge


Address:    


Telephone:    

Email:    

Consulting Agreement—Conformis, Inc. / J. Brent Alldredge
January 17, 2022        Page 6


EXHIBIT A
SCOPE OF SERVICES
Upon written request by the Company during the Term, the Consultant “Services” to the Company will include:
1.General consulting services as may be requested by the Company's Chief Executive Officer or his designee, including, without limitation:

a.Preparation of board materials that are regularly prepared by the Company’s Chief Legal Officer relating to the Company’s board and committee meetings scheduled for February 8, 2021; and

b.Providing transition services to the Company’s Legal team, and to any interim or successor Chief Legal Officer engaged by the Company, as the case may be.

The Consultant will report to the Company’s Chief Executive Officer or his designee. The Consultant will provide Services at such places and times as the Company and the Consultant may mutually determine.
The Company will not control in any way the methods used by the Consultant in performing the Services.
This Agreement will automatically terminate on February 25, 2022. The parties hereto may extend the term of this Agreement by means of a written instrument executed by each of them, including in counterparts.

Consulting Agreement—Conformis, Inc. / J. Brent Alldredge
January 17, 2022        Page 7


EXHIBIT B
CONSULTING FEES
The Company will pay the Consultant for Services rendered:
1.At the rate of five hundred dollars ($500.00) per hour; provided, however, that compensation shall not exceed five thousand dollars ($5,000.00) (equivalent to ten (10) hours) per calendar week in which actual Services are provided, unless approved in writing and in advance by the Company’s Chief Executive Officer.
2.Upon the expiration or termination of this Agreement on February 25, 2022, so long as the Consultant has rendered Services in good faith, and upon the Company’s receipt of the executed Termination Certificate (Exhibit C), the total sum of ten thousand dollars ($10,000.00).
Other than as set forth above, the Company will pay the Consultant no other compensation, whether in cash or non-cash form, for the Services.


Consulting Agreement—Conformis, Inc. / J. Brent Alldredge
January 17, 2022        Page 8


EXHIBIT C
TERMINATION CERTIFICATE
This is to certify that I do not have in my possession, nor have I failed to return, any papers, records, data, notes, drawings, files, documents, samples, devices, products, equipment, designs, computer programs or other materials, including copies and reproductions of any of the aforementioned items, in whatever form, relating to Conformis, Inc. (the “Company”), whether or not confidential or proprietary.
I further certify that I have complied with all the terms of the Consulting Agreement by and between the Company and the undersigned dated as of December 22, 2021 with a deemed Effective Date of January 17, 2022 (the “Consulting Agreement”).
Moreover, I acknowledge and agree that, in compliance with the Consulting Agreement, I will hold in confidence and will not disclose, use, copy, publish, summarize or, if applicable, remove from the premises of the Company any “Confidential Information” (as defined in the Consulting Agreement).


Date: ____________________


    
J. Brent Alldredge
Consulting Agreement—Conformis, Inc. / J. Brent Alldredge
January 17, 2022        Page 9
EX-99.1 3 ex-991_pressreleasex122320.htm EX-99.1 Document

Conformis, Inc. Announces Departure of Chief Legal Officer, Corporate Secretary
BILLERICA, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Brent Alldredge, Chief Legal Officer and Corporate Secretary, has notified the Company that he will be departing the Company on January 16, 2022 to become the General Counsel at Bruker Corporation, a global, publicly traded developer, manufacturer, and distributor of scientific instruments and analytical and diagnostic solutions.
As a result, the Company’s Board of Directors has begun a search to appoint a successor to Mr. Alldredge, with a further announcement to be made in due course. Mr. Alldredge has agreed to work with the Company as an advisor to help achieve a smooth transition.
“Since joining Conformis in 2019, Brent has been a trusted advisor and valued member of the executive management team. His new position at a multi-billion dollar, large market cap company is an indication of his experience and capabilities,” said Mark Augusti, President and Chief Executive Officer.  “On behalf of the Company and the Board, I would like to thank Brent for his hard work and significant contributions.”
“It has been a privilege,” said Mr. Alldredge, “to work with a strong management team that is dedicated to maximizing the potential of Conformis’ unique technologies and service offerings to benefit patients, surgeons, and shareholders. Considering the Company’s state-of-the-art technology and the ongoing evolution of its products and service offerings, I am confident that Conformis is well positioned for future success.”
About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient's unique anatomy.  Conformis also offers Identity Imprint™, a new line of total knee replacement products that utilizes a proprietary algorithm to select the implant size that most closely meets the geometric and anatomic requirements of the patient’s knee. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments.  Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com.  To receive future releases in e-mail alerts, sign up at ir.conformis.com
Cautionary Statement Regarding Forward-Looking Statements



Statements in this press release about our future expectations, plans and prospects, the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these terms or other and similar expressions are intended to identify forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties; risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Investor Contact
ir@conformis.com
(781) 374-5598
image_0.jpg
Source: Conformis, Inc.



EX-101.SCH 4 cfms-20211223.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 cfms-20211223_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key EX-101.PRE 6 cfms-20211223_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image_0.jpg begin 644 image_0.jpg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htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Dec. 23, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 23, 2021
Entity Registrant Name Conformis, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37474
Entity Tax Identification Number 56-2463152
Entity Address, Address Line One 600 Technology Park Drive
Entity Address, City or Town Billerica
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01821
City Area Code 781
Local Phone Number 345-9001
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.00001 par value per share
Trading Symbol CFMS
Entity Emerging Growth Company false
Entity Central Index Key 0001305773
Amendment Flag false
XML 9 cfms-20211223_htm.xml IDEA: XBRL DOCUMENT 0001305773 2021-12-23 2021-12-23 0001305773 false 8-K 2021-12-23 Conformis, Inc. DE 001-37474 56-2463152 600 Technology Park Drive Billerica MA 01821 781 345-9001 false false false false Common Stock, $0.00001 par value per share CFMS false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.conformis.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cfms-20211223.htm cfms-20211223.xsd cfms-20211223_lab.xml cfms-20211223_pre.xml ex-101_balldredgeconsultin.htm ex-991_pressreleasex122320.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cfms-20211223.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "cfms-20211223.htm" ] }, "labelLink": { "local": [ "cfms-20211223_lab.xml" ] }, "presentationLink": { "local": [ "cfms-20211223_pre.xml" ] }, "schema": { "local": [ "cfms-20211223.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 22, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cfms", "nsuri": "http://www.conformis.com/20211223", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cfms-20211223.htm", "contextRef": "i45d05afdb8c847c8b582cb627d826ac6_D20211223-20211223", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.conformis.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cfms-20211223.htm", "contextRef": "i45d05afdb8c847c8b582cb627d826ac6_D20211223-20211223", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.conformis.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r4": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r5": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001305773-21-000142-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001305773-21-000142-xbrl.zip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